Get All Access for FREE

Market News & Research,
Fundamental Data,
Live Transcripts & Audio,
AlphaGraphics,

and a whole lot more…

{{::item.ticker}} • {{::item.company_name}} No Results

Get All Access for FREE

Market News & Research,
Fundamental Data,
Live Transcripts & Audio,
AlphaGraphics,

and a whole lot more…

News & Research
Portfolio
Discover
Groups
$A {{ '2017-08-15T21:40:22+0000' | timeago}} • Webcast

$A said the improved performance of its pathology division showed the company is regaining market share. In 3Q17, currency had a positive impact on revenues and operating profit, of $7MM and $1M respectively. Adjusted operating margin for fiscal 2017 is expected to be 21.8%, higher by 110 basis points compared to last year.

$A {{ '2018-05-14T21:28:37+0000' | timeago}} • Infographic

$A Agilent Technologies, Inc. Earnings AlphaGraph: Q2 2018 Highlights

$A {{ '2018-01-19T17:03:14+0000' | timeago}} • Announcement

$A elected Dow Wilson, CEO of Varian Medical Systems Inc., to its BoD, effective March 20, 2018. Wilson is also a board member of AdvaMed, a U.S. trade association representing 80% of the medical technology firms in the U.S., and Varex Imaging Corp., which was created through the successful spin-off of Varian Medical.

$A {{ '2018-01-09T19:50:20+0000' | timeago}} • Announcement

$A acquired Cork, Ireland-based Luxcel Biosciences, a developer of real-time fluorescence plate-reader based in vitro cell assay kits. This acquisition expands $A's cell analysis portfolio with the addition of easy-to-use assay kits that are compatible with industry standard plate-readers.  Financial terms of the deal were not disclosed.

$A {{ '2017-11-21T15:04:12+0000' | timeago}} • Webcast

For FY18, $A expects pharma to moderate down slightly from a 6% growth rate delivered in FY17. Agilent expects China to maintain a high-single-digit growth rate. For Europe and the chemical and energy markets, while Agilent experienced unexpectedly strong FY17 growth, the company cautiously guided to lower growth in FY18.

$A {{ '2017-11-20T21:43:30+0000' | timeago}} • Announcement

$A expects 1Q18 revenue of $1.145-1.165Bil. First-quarter non-GAAP earnings are expected to be in the range of $0.55 to $0.57 per share. For FY18, Agilent expects revenue of $4.72-4.74Bil and non-GAAP earnings of $2.50-2.56 per share.

$A {{ '2017-11-20T21:40:09+0000' | timeago}} • Announcement

With net revenue soaring 7% to $1.19Bil in 4Q17, $A posted a 40% jump in net income of $177MM or $0.54 per diluted share.

$A {{ '2017-09-22T21:43:23+0000' | timeago}} • Announcement

$A said its Dako PD-L1 IHC 22C3 pharmDx assay has an expanded label approved by the US FDA to aid in identifying gastric or GEJ adenocarcinoma patients for treatment with KEYTRUDA, an anti-PD-1 therapy manufactured by $MRK. These approvals mean these patients have the possibility of receiving a targeted anti-PD-L1 immunotherapy.

$A {{ '2017-09-20T20:44:35+0000' | timeago}} • Announcement

$A has declared a quarterly dividend of 13.2 cents per share on its common stock. The dividend will be paid on October 25, 2017, to shareholders of record on October 3, 2017.

$A {{ '2017-09-19T15:03:27+0000' | timeago}} • Announcement

$A said FDA has approved the cancer diagnostic known as PD-L1 IHC 28-8 pharmDx for use in cases of urothelial carcinoma and of squamous cell carcinoma of the head and neck. The test had previously been approved for melanoma as well as non-squamous, non-small-cell lung cancer (NSCLC).

$A {{ '2017-09-13T19:05:54+0000' | timeago}} • Announcement

$A has obtained approval from the US FDA for the GenetiSure Dx Postnatal Assay, its first comparative genomic hybridization (CGH) assay for diagnostic use. This assay enables clinical geneticists to detect genetic aberrations associated with developmental delay, intellectual disabilities and congenital irregularities more accurately.

$A {{ '2017-08-23T13:21:45+0000' | timeago}} • Announcement

Life sciences company $A filed a lawsuit against its former employees and Shanghai Echrom Electronic Technology, alleging infringement of trade secrets. The suit seeks compensation for the loss and stoppage of the use of Agilent's proprietary technologies by Shanghai Echrom and others. The employees allegedly obtained the trade secrets illegally.

$A {{ '2017-08-15T22:33:18+0000' | timeago}} • Webcast

$A expects the recently acquired Cobalt Light Systems to deliver double-digit growth. Agilent anticipates some of its ongoing chemical trials to result in commercial production in the coming years. Capex is expected to be lower in FY18 than in FY17, while the pharma business growth is seen accelerating to high-double digits in the coming quarters.

$A {{ '2017-08-15T21:58:28+0000' | timeago}} • Webcast

$A raised its outlook of operating cash flow for FY17 to $860MM from the earlier forecast of $825MM, while lowering the Capex guidance to $285MM. The free cash flow outlook has been raised by $40MM to $665MM. Attributing the strong 3Q17 results to its competitive product portfolio, Agilent said measures are afoot to expand capacity to meet demand.

$A {{ '2017-08-15T21:40:22+0000' | timeago}} • Webcast

$A said the improved performance of its pathology division showed the company is regaining market share. In 3Q17, currency had a positive impact on revenues and operating profit, of $7MM and $1M respectively. Adjusted operating margin for fiscal 2017 is expected to be 21.8%, higher by 110 basis points compared to last year.

$A {{ '2017-08-15T21:09:40+0000' | timeago}} • Infographic

$A Agilent Technologies, Inc. Earnings AlphaGraph: Q3 2017 Highlights

$A {{ '2017-08-15T20:32:02+0000' | timeago}} • Announcement

$A said it expects to record non-GAAP earnings in the range of $0.60 per share to $0.62 per share in 4Q17, on revenues of $1.15-$1.17Bil. For fiscal 2017, Agilent is looking for revenues between $4.435Bil and $4.455Bil. Full year non-GAAP earnings are forecast to be in the range of $2.29 per share to $2.31 per share.

$A {{ '2017-08-15T20:26:59+0000' | timeago}} • Announcement

Diversified technology company $A reported a 41% growth in 3Q17 profit. Earnings rose to $0.54 per share from $0.38 per share a year earlier as revenues moved up 7% to $1.1Bil. The strong growth was supported by new product launches and improved performance by all business segments. On a non-GAAP basis, earnings climbed 20% to$0.59 per share.

$A {{ '2017-08-15T20:24:30+0000' | timeago}} • Announcement

Diversified technology company $A reported a 41% growth in 3Q17 profit. Earnings rose to $0.54 per share from $0.38 per share a year earlier as revenues moved up 7% to $1.1Bil. The strong growth was supported by new product launches and improved performance by all business segments. On a non-GAAP basis, earnings climbed 20% to$0.59 per share.

$A {{ '2017-07-19T12:28:12+0000' | timeago}} • Announcement

$A has appointed Hans E Bishop to its BoD. Bishop is a co-founder and CEO of Seattle-based biopharmaceutical firm Juno Therapeutics. He has held various executive positions in the pharmaceutical industry, including as COO of Dendreon.

$A {{ '2017-07-17T17:47:21+0000' | timeago}} • Announcement

$A introduced a new sequencing library prep solution, Agilent SureSelectXTHS. SureSelectXTHS is a streamlined, high-sensitivity solution for research, optimized for labs with a requirement to sequence DNA from formalin-fixed paraffin-embedded (FFPE) samples, which may have degraded over time.

Recent Transcripts
PKE | Earnings
June 22nd 2018, 3:00pm
MEI | Earnings
June 21st 2018, 3:00pm
JBL | Earnings
June 14th 2018, 8:30pm
MRVL | Earnings
May 31st 2018, 8:45pm
AlphaGraphics you may like
Related Feed
Recent Transcripts
PKE | Earnings
June 22nd 2018, 3:00pm
MEI | Earnings
June 21st 2018, 3:00pm
JBL | Earnings
June 14th 2018, 8:30pm
MRVL | Earnings
May 31st 2018, 8:45pm
AlphaGraphics you may like